Navigation Links
Alzheimer's Drug Shows Promise in Early Trial
Date:7/18/2012

WEDNESDAY, July 18 (HealthDay News) -- Researchers say an investigational drug helped improve memory, language, attention and other mental skills in people with early Alzheimer's disease.

The study was funded by EnVivo Pharmaceuticals, which is developing the drug, dubbed EVP-6124. The results are to be presented Wednesday at the annual meeting of the Alzheimer's Association in Vancouver.

The study involved 409 patients with mild to moderate Alzheimer's disease who were either being treated with the drugs donepezil (Aricept) or rivastigmine (Exelon) or were receiving no treatment.

During the six-month, phase 2 trial, patients took either a placebo or one of three different doses of EVP-6124.

After 23 weeks of treatment, the patients in the high-dose group showed statistically significant benefits on tests of mental function compared to those taking the dummy pill. Some patients in the medium- and high-dose groups did experience mild to moderate gastrointestinal side effects, the team added.

"In our study, EVP-6124 provided significant benefits for people with mild to moderate Alzheimer's whether they were on currently approved therapy or not," Dr. Dana Hilt, senior vice president of clinical development and chief medical officer of EnVivo, said in an Alzheimer's Association news release.

The authors explain that EVP-6124 belongs to a family of drugs called alpha-7 nicotinic agonists, which amplify the effects of acetylcholine, a brain chemical that's essential for normal brain and memory function. People with Alzheimer's disease have greatly reduced levels of acetylcholine.

Currently, there are no effective treatments to fight Alzheimer's disease, although certain drugs may temporarily ameliorate symptoms.

For that reason, the new study "is potentially interesting, as there is a need for better symptomatic treatment of Alzheimer's disease," said Peter Davies, director of the Litwin Zucker Research Center for the Study of Alzheimer's Disease at the Feinstein Institute for Medical Research in New Hyde Park, N.Y.

He pointed out that the mechanism behind the new drug is not altogether novel. "Treating the deficiency of acetylcholine is the basis for the already approved drugs Aricept, Exelon and Razodyne," Davies said. "This drug does the same thing, but in a different way. The other drugs act to reduce the breakdown of acetylcholine: this drug mimics the effect of acetylcholine at one of the receptors for this compound."

He said that there are hints that this approach might do more than just ease symptoms, and might attack the underlying illness. But that remains speculative and "further studies do seem to be warranted," Davies said.

Another expert agreed.

"These promising effects are 'symptomatic' (the drug does not slow progression of disease), and the study is relatively small in size," noted Stephen Ferris, director of the Alzheimer's Disease Center and the clinical trials program at NYU Langone Medical Center's Comprehensive Center on Brain Aging in New York City.

Like Davies, Ferris stressed that "if the results can be confirmed in a larger trial, the drug would be an important addition to current Alzheimer treatments."

Findings presented at medical meeting are typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease medications.

-- Robert Preidt

SOURCES: Peter Davies, Ph.D., director, Litwin Zucker Research Center for the Study of Alzheimer's Disease, Feinstein Institute for Medical Research, New Hyde Park, N.Y.; Steven H. Ferris, Ph.D., Friedman Professor and director, Alzheimer's Disease Center and the clinical trials program, Comprehensive Center on Brain Aging, NYU Langone Medical Center, New York City; Alzheimer's Association, news release, July 18, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's Drug Shows Promise in Early Trial
(Date:7/27/2017)... ... 27, 2017 , ... Somnoware, a leading provider of digital ... solution to its healthcare management platform. This solution provides physicians with remote scoring ... of scoring in the cloud is on par with doing it on a ...
(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... The Los Angeles leg of the US ... 2017 at 7:00pm and will be held at the Clive Davis Theater inside the Grammy ... Camo Jacket, chronicles the story of the iconic Welsh rock musician, Mike Peters (of The ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the ... to the men’s pro squad as a stagiaire for the remainder of the 2017 ... debut on July 31st at the Tour of Utah. , “Every season we are ...
(Date:7/26/2017)... ... July 26, 2017 , ... Capillus, LLC has announced the redesign of ... new Flexible Fitting Design offers a more comfortable, adaptable fit and is available for ... improvements to the home-use laser therapy caps intended to improve both user experience and ...
(Date:7/26/2017)... ... ... A major challenge many labs face is a direct result from a ... dry cycle are a few common challenges that can overcome when following best practices. ... and advancements in laboratory freeze dryers that will improve quality and reduce the time ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 E.I. Medical Imaging (EIMI) ... Bimini SharkLab to custom design the worlds first ultrasound system to ... in their native habitat. In preparation for a piece produced ... Shark Week, Dr. Guttridge approached EIMI with the idea ... directly to hammerhead sharks underwater. ...
Breaking Medicine Technology: